

MY 5 TOP TAKES

EFFICACY OF CEFTAZIDIME-AVIBACTAM IN MONOTHERAPY OR COMBINATION THERAPY AGAINST CARBAPENEM RESISTANT GRAM NEGATIVE ORGANISMS: A META-ANALYSIS




11 Retrospective cohort studies

396 patients
(194 monotherapy;
202 combination therapy)

Site of Infection:

- Pneumonia
- Bacteremia
- Intra-abdominal infection
- Urinary tract infection
- Skin & Soft tissue infection
- Bone & Joint infection



Antibiotics including

- Colistin
- Tigecycline
- Aminoglycosides
- Fosfomycin
- Ciprofloxacin

Median Duration of Treatment:

13 - 21 days



Mortality Rate

Monotherapy: 30.9%

Combination therapy: 38.1%

Relative Risk: 1.18
(95% CI 0.88 - 1.58)

No difference between
Monotherapy and
Combination Therapy



Microbiological Outcome

Monotherapy: 63.4%

Combination therapy: 64.9%

Relative Risk: 1.04
(95% CI 0.85 - 1.28)

No difference between
Monotherapy and
Combination Therapy

TAKE HOME MESSAGE

NO DIFFERENCE BETWEEN CEFTAZIDIME/AVIBACTAM MONOTHERAPY & COMBINATION THERAPY

Ceftazidime/avibactam in monotherapy or in combination therapy for the treatment of infections due to Carbapenem Resistant Gram Negative Organisms showed **SIMILAR EFFECT** on the mortality rate and microbiological cure.

[Click here to read the paper](#)